MS |
Mastocytosis |
TEP |
Technical Expert Panel |
PRISMA-ScR |
Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews |
IFN-alfa |
Interferone alfa |
SM |
systemic mastocytosis |
SCF |
stem cell factor |
ISM |
Indolent sistemic mastocytosis |
KIT |
gene encoding tyrosine kinase protein |
BMD |
Bone mineral density |
SM-AHNMD |
systemic mastocytosis with associated clonal non-mast cell hematologic disease |
MC |
mast cell |
NSAIDs |
non-steroidal anti-inflammatory drugs |
DEXA |
dual-energy X-Ray absorptiometry |
DKK-1 |
Dickkopf-1 |
SOST |
sclerostin |
BTM |
bone turnover marker |
PAM |
pamidronate |
CTX |
C-terminal collagen type I telopeptide |
bALP |
bone alkaline phosphatase |
FFx |
fractures |
BMM |
bone marrow mastocytosis |
RANKL |
nuclear factor kappa-B ligand |
PPARγ |
peroxisome proliferator-activated receptor gamma |
AdvSM |
Advanced sistemi mastocytosis |
TGF-beta |
tumor growth factor-beta |
VEGF |
vascular endothelial growth factor |
FGF |
Fibroblast growth factor |
WNT |
wingless-related integration site |